-
Plerixafor (AMD3100): Assay Workflow Guide
2026-09-27
A scenario-driven guide to using Plerixafor (AMD3100), SKU A2025, in viability, chemotaxis, and CXCR4-focused experiments. It connects product specifications with assay controls, practical handling, and evidence-based interpretation of cancer and cell-mobilization findings.
-
Ceapin-A7 for ATF6α Pathway Dissection
2026-09-26
Use Ceapin-A7 to isolate the ATF6α branch of the unfolded protein response—not to switch off every ER stress pathway. This workflow pairs branch-specific target engagement with a nucleus pulposus cell pyroptosis model, helping distinguish ATF6α activity from the PERK–JAK1–STAT3 mechanism reported in recent research.
-
Fumagillin Workflows for Angiogenesis Research
2026-09-25
Use Fumagillin to investigate MetAP-2-dependent endothelial responses and to design carefully controlled antiparasitic screening assays. A landmark soft-tunic-syndrome study classified it as moderately active in vitro, while its in vivo findings support other tested agents—not Fumagillin—so the two research paths require distinct evidence and validation.
-
PXR Activation Links Liver Regeneration and CYP Activity
2026-09-25
A rat study reports that activating pregnane X receptor (PXR) can promote liver enlargement while increasing CYP3A1/2 and CYP2C6/11 metabolic activity, including after partial hepatectomy. Its probe-drug and liver-protein measurements help distinguish organ regrowth from the recovery of drug-metabolizing function, while highlighting important limits in translating rat findings to human pharmacology.
-
miR-24-3p–Sp1/PI3K Axis in Doxorubicin Heart Failure
2026-09-24
In doxorubicin-induced heart-failure models, miR-24-3p increased as Sp1 and PI3K expression fell, while miR-24-3p silencing reduced cellular injury and improved pathway-associated readouts. The study combines rat and H9c2 models with pathway perturbation and target validation, identifying the miR-24-3p/Sp1/PI3K axis as a candidate mechanism for further cardioprotection research—not an established treatment.
-
Necrosulfonamide: Practical Necroptosis Assay Guidance
2026-09-24
A scenario-driven guide to using Necrosulfonamide (SKU B7731) in necroptosis and cell-death experiments. It explains target engagement, model-specific interpretation, formulation, and practical criteria for comparing suppliers without overstating the available evidence.
-
Ro 3306 for Cell-Cycle-Resolved mTORC1 Studies
2026-09-24
Ro 3306 is a selective CDK1 inhibitor that can help define how late-G2 blockade shapes cell-cycle experiments. This guide connects its use to phase-specific mTORC1 findings and explains how to separate arrest effects from underlying signaling biology.
-
A40926 Workflow: From MIC Assay to Dalbavancin
2026-09-23
A40926 is a dalbavancin precursor that connects precise cell-wall inhibition studies with glycopeptide pathway engineering. This practical guide covers assay setup, MRSA and Neisseria applications, comparative controls, troubleshooting, and translation limits.
-
Triazole ALDH2 Activators for Myocardial Ischemia
2026-09-22
The reference study reports a triazole-based series of aldehyde dehydrogenase 2 (ALDH2) activators designed with molecular simulation to improve both activity and water solubility. Lead compound Z17 produced strong ALDH2 activation and improved cardiac, infarct, and biomarker outcomes in a mouse ischemia-reperfusion model, supporting further preclinical development rather than establishing clinical efficacy.
-
MLKL Polymerization and Lysosomal Membrane Permeabilization
2026-09-22
Liu and colleagues identify lysosomal membrane permeabilization as a direct execution event in necroptosis, showing that polymerized MLKL reaches lysosomal membranes, promotes lysosome clustering and fusion, and releases cathepsins into the cytosol. The work places cathepsin B downstream of MLKL polymerization and provides a mechanistic framework for interpreting lysosomal damage during regulated cell death.
-
SGI-1027 and Everolimus in Renal Cancer
2026-09-21
A study in Advanced Science identifies SGI-1027 as a methuosis inducer and shows that it cooperates with everolimus to suppress renal cancer through lysosomal membrane permeability, apoptosis, and GSDME-dependent pyroptosis. The findings provide a mechanistic framework for combining mTOR inhibition with noncanonical cell-death pathways to address everolimus resistance.
-
Standardized Whole-Blood Stimulation in Immunometabolism
2026-09-21
Zhao and colleagues present a standardized whole-blood stimulation protocol that combines pathogen-associated immune stimuli with metabolic pathway modulation and cytokine measurement. The workflow provides a practical framework for comparing donor responses and examining how metabolic interventions, including mycophenolic acid-related IMPDH inhibition, selectively reshape immune signaling.
-
Biotin-HPDP for Reversible Thiol Labeling
2026-09-20
Biotin-HPDP enables selective labeling of accessible cysteine thiols while preserving a reversible disulfide linkage for affinity capture and release. Its workflow is especially useful for biotin-switch assays, detection of S-nitrosylated proteins, and mechanistic studies of redox-regulated plant stress proteins.
-
Sabutoclax in Reliable Apoptosis Assays
2026-09-19
Learn how Sabutoclax (SKU A4199) can clarify viability, proliferation, and apoptosis results in cancer-cell assays. This scenario-based guide connects pan-Bcl-2 pharmacology with practical stock preparation, controls, data interpretation, and evidence-based product selection.
-
Plerixafor (AMD3100) for CXCR4 Research
2026-09-19
Plerixafor (AMD3100) converts CXCL12/CXCR4 signaling into a controllable variable for cancer migration, stem-cell trafficking, and immune-cell redistribution studies. This practical guide connects compound handling with assay design, comparative benchmarking, troubleshooting, and translational interpretation.